AstraZeneca May Rethink Aversion to Big Deals After Setbacks

AstraZeneca Plc’s pledge to avoid big acquisitions may be tested after setbacks for three of the company’s most promising drugs in development.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.